IRCT20161010030246N3招募中3 期
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicity in hospitalized patients at Imam Reza & Vali-Asr hospitals in Birjand
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •The patient's hemodynamic stability
- •The desire to participate in the study
- •Gentamicin is given intravenous or intramuscular for at least 1 week at a dose of 5 mg / kg / day or 80-100 mg / TDS
- •No history of confirmed acute kidney injury.
- •No history of confirmed chronic kidney injury.
- •No use of gentamicin by intravenous or muscle in the past 14 days.
- •No history of confirmed allergic reactions following oral administration of silymarin
- •No history of confirmed allergic reactions following oral administration of silymarin
- •Do not receive medications or antioxidant compounds such as vitamin C, vitamin E or vitamin A
- •Do not receive high-renal toxicity medicines at the same time
- •Oral tolerance to medications
排除标准
- 未提供
研究者
相似试验
尚未招募
2 期
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
尚未招募
3 期
Evaluating the effectiveness of silymarin in preventing vancomycin nephrotoxicityVancomycin-induced nephrotoxicity in hospitalized patients.Drug- and heavy-metal-induced tubulo-interstitial and tubular conditionsIRCT20161010030246N6Shiraz University of Medical Sciences80
已完成
3 期
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64
招募中
3 期
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
尚未招募
3 期
Effect of silymarin in the treatment of patients with depressioIRCT20160804029191N4Mashhad University of Medical Sciences80